account/PRNewswire/ -- Abbott (NYSE: ABT) today announced it filed premarket approval applications to the U.S. Food and Drug Administration and the Japanese Ministry of Health, Labour, and Welfare for a new molecular diagnostic test designed to detect abnormal...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Abbott Completes Submission Of New Molecular Test Intended For Non-small-cell Lung Cancer Therapy Selection
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account